On January 17, 2025, the Biden U.S. Department of Agriculture (USDA) issued an interim final rule with a request for comment ...

PRINCETON - PDS Biotechnology Corporation (NASDAQ:PDSB) has confirmed plans to commence its VERSATILE-003 Phase 3 clinical trial for a promising cancer immunotherapy within the first quarter of 2025.

MALVERN, Pa. - Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company trading near its 52-week low of $2.99, has announced the initiation of a Phase 3 trial for its Alzheimer's disease ...

Amid the federal funding uncertainty for health and sciences, local life science leaders say this could be a moment for industry partners, investors and others to step up and support the sector.